Last reviewed · How we verify
NCT06050434: PROTraSarc
Prospective Study to Evaluate Patient Reported Outcomes (PRO) During Rechallenge With Trabectedin in Sarcoma Patients
trial in Soft Tissue Sarcoma in 7 participants. Terminated before completion.
30 July 2024
Quick facts
| Lead sponsor | Institut für Klinische Krebsforschung IKF GmbH at Krankenhaus Nordwest |
|---|---|
| Status | Terminated |
| Study type | OBSERVATIONAL |
| Enrollment | 7 |
| Start date | 31 October 2023 |
| Primary completion | 30 July 2024 |
| Estimated completion | 30 July 2024 |
| Sites | 9 locations across Germany |
Conditions studied
- Soft Tissue Sarcoma — all drugs for Soft Tissue Sarcoma →
Sponsor
Institut für Klinische Krebsforschung IKF GmbH at Krankenhaus Nordwest — full company profile →
Who can join
18 and older, any sex, with Soft Tissue Sarcoma. Patients with the condition only — healthy volunteers not accepted.
Sponsor's own description
Chemotherapy with Trabectedin is an effective treatment for sarcoma patients in the second line setting or in first line for patients who are deemed unsuitable to receive anthracycline therapy. The prospective study will primarily investigate the PRO of Trabectedin rechallenge in patients with soft tissue sarcomas that had to discontinue initial Trabectedin treatment due to various reasons such as progression, side effects or surgery, as is commonly the case in real-life settings. Embedding this trial in the GISAR registry enables the evaluation of a large number of patients with long-term follow-up which allows multiple analyses regarding different questions that remain unanswered until today.
Publications & conference data
No peer-reviewed publications indexed yet for this trial.
Verify or expand the search:
- PubMed search for NCT06050434
- Europe PMC full search
- ASCO Meeting Library
- ESMO Meeting Library
- bioRxiv preprints
- medRxiv preprints
- Google Scholar
Related trials
Other recruiting trials for Soft Tissue Sarcoma
Currently open trials in the same condition.
- NCT07261631 — Phase I Study of [177Lu]Lu-DFC413 in Patients With Solid Tumors · Phase 1 · recruiting
- NCT07243626 — Efficacy and Safety of Envafolimab Plus Doxorubicin and Ifosfamide for Advanced Soft Tissue Sarcoma · Phase 2 · recruiting
- NCT07049848 — SATURN-STS: Phase II Study of Neoadjuvant Atezolizumab With Doxorubicin, Concurrent Atezolizumab With Pre-operative Radi · Phase 2 · recruiting
- NCT06962072 — Outcomes Following Limb Sparing Surgery for Soft Tissue Sarcoma · recruiting
- NCT06905132 — Preoperative 5-Day Radiotherapy for Soft Tissue Sarcoma · Phase 2 · recruiting
Other Institut für Klinische Krebsforschung IKF GmbH at Krankenhaus Nordwest trials
Trials by the same sponsor.
- NCT07507968 — TNT With FLOT/Durvalumab Plus Post-OP Durvalumab for Resectable Gastroesophageal Adenocarcinoma · Phase 2 · not yet recruiting
- NCT07510724 — Real-World Data on the Treatment of Lung Cancer Patients With the Immune-Checkpoint Inhibitor Tislelizumab · recruiting
- NCT07365930 — NIS on the Benefits of TIPS in Patients With HCC Receiving Atezo+Bev in 1st-Line Therapy · recruiting
- NCT06856837 — - IKF/AIO-QUINTIS - Evaluating Fruquintinib in Combination With Tislelizumab in Microsatellite Stable / Proficient Misma · Phase 2 · recruiting
- NCT06731803 — Platform Trial Evaluating Treatment of Neoadjuvant Trastuzumab-deruxtecan Containing Combination Therapies for HER2+, Re · Phase 1, PHASE2 · recruiting
Verify against primary sources
- ClinicalTrials.gov — authoritative US registry record
- WHO ICTRP — international registry index
- EU Clinical Trials Register
- Sponsor press releases (Google)
- Trial protocol + status: ClinicalTrials.gov NCT06050434 (US National Library of Medicine, public domain)
- Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
- Sponsor: as reported to ClinicalTrials.gov by Institut für Klinische Krebsforschung IKF GmbH at Krankenhaus Nordwest
- Last refreshed: 1 December 2025
Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT06050434.
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing